Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of YL202 versus investigator's choice in previously treated HR-positive/HER2-negative unresectable locally advanced or metastatic breast cancer
CTR20260709Phase 3Active
- Sponsor
- MediLink Therapeutics
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of YL202 in breast cancer, sponsored by MediLink Therapeutics. Started Apr 2026; status: active.
02
Drugs
YL202
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20260709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260709.